Wall Street brokerages forecast that Xencor Inc (NASDAQ:XNCR) will announce sales of $6.73 million for the current fiscal quarter, Zacks reports. Four analysts have provided estimates for Xencor’s earnings. The highest sales estimate is $10.30 million and the lowest is $4.07 million. Xencor reported sales of $11.56 million during the same quarter last year, which would suggest a negative year-over-year growth rate of 41.8%. The business is expected to issue its next quarterly earnings report on Monday, February 24th.
On average, analysts expect that Xencor will report full year sales of $159.92 million for the current fiscal year, with estimates ranging from $157.26 million to $163.50 million. For the next year, analysts expect that the company will report sales of $63.45 million, with estimates ranging from $24.89 million to $112.16 million. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that follow Xencor.
Xencor (NASDAQ:XNCR) last announced its quarterly earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.58) by $0.40. The business had revenue of $21.76 million for the quarter, compared to analyst estimates of $4.62 million. Xencor had a return on equity of 5.84% and a net margin of 21.60%.
Several research analysts have issued reports on the company. ValuEngine upgraded Xencor from a “buy” rating to a “strong-buy” rating in a report on Friday. Zacks Investment Research lowered Xencor from a “buy” rating to a “hold” rating in a report on Saturday, November 16th. Mizuho restated a “buy” rating on shares of Xencor in a report on Tuesday, November 5th. Leerink Swann dropped their target price on Xencor from $52.00 to $44.00 and set an “outperform” rating on the stock in a report on Wednesday, November 6th. Finally, BidaskClub lowered Xencor from a “strong-buy” rating to a “buy” rating in a report on Friday. One analyst has rated the stock with a sell rating, three have issued a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $43.90.
Shares of NASDAQ:XNCR opened at $37.50 on Friday. The business’s 50 day simple moving average is $36.98 and its two-hundred day simple moving average is $37.46. The firm has a market cap of $2.13 billion, a P/E ratio of -28.63 and a beta of 1.38. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.92 and a current ratio of 8.92. Xencor has a 52-week low of $27.75 and a 52-week high of $46.33.
In other news, major shareholder John S. Stafford III sold 120,324 shares of the firm’s stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $41.64, for a total value of $5,010,291.36. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, major shareholder John S. Stafford III sold 37,951 shares of the firm’s stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $38.68, for a total value of $1,467,944.68. The disclosure for this sale can be found here. 4.33% of the stock is owned by company insiders.
Several institutional investors and hedge funds have recently modified their holdings of XNCR. Quantamental Technologies LLC purchased a new stake in shares of Xencor during the second quarter valued at approximately $76,000. Royal Bank of Canada increased its position in shares of Xencor by 42.7% during the second quarter. Royal Bank of Canada now owns 2,004 shares of the biopharmaceutical company’s stock valued at $82,000 after acquiring an additional 600 shares during the last quarter. Aperio Group LLC purchased a new stake in shares of Xencor during the second quarter valued at approximately $152,000. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Xencor by 42.2% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,911 shares of the biopharmaceutical company’s stock valued at $160,000 after acquiring an additional 1,160 shares during the last quarter. Finally, Bank of Montreal Can purchased a new stake in shares of Xencor during the second quarter valued at approximately $163,000. 92.43% of the stock is owned by institutional investors.
Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and other protein therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions.
Featured Article: Cost of Debt
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.